DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening for Drug Repositioning and Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) is a curated collection of 2,320 bioactive compounds approved by major global regulatory agencies, offered by APExBIO (product page). Each compound is pre-dissolved at 10 mM in DMSO and formatted for high-throughput and high-content screening workflows (HTS/HCS). The library's mechanism-diverse portfolio supports both target identification and drug repositioning across disease models, including cancer and neurodegeneration (contrast: HDAC1.com article covers application breadth, this article details evidence and pitfalls). Recent peer-reviewed studies have demonstrated the discovery of novel disease-modifying mechanisms, such as the inhibition of the OSCAR-PPARγ axis in osteoarthritis, through FDA-approved compound screening (Kim et al., 2024, DOI:10.1038/s41467-024-45174-6). All solutions are stable for 12 months at -20°C and up to 24 months at -80°C.

Biological Rationale

Drug repositioning leverages the established safety and clinical data of FDA-approved compounds, reducing the cost and time of new therapeutic discovery. Screening well-characterized drugs enables rapid identification of modulators for new targets, as the mechanism of action (MOA) is often known (see: PrecisionFDA.net; this article provides granular benchmarks and pitfalls not addressed there). The DiscoveryProbe™ FDA-approved Drug Library includes compounds with diverse MOAs—receptor agonists/antagonists, enzyme inhibitors, ion channel modulators, and pathway regulators. This diversity is essential for probing complex biological systems and uncovering pleiotropic drug activities. Such libraries also facilitate systems biology approaches, enabling broad phenotypic screens and pathway mapping (compared to Cytochrome-c-fragment-93-108.com, this article updates with new osteoarthritis findings).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ library encompasses 2,320 small molecules with established clinical indications and detailed MOA annotations. Compounds represent multiple pharmacological classes:

• Enzyme inhibitors: e.g., doxorubicin (topoisomerase II inhibitor), metformin (AMPK activator).
• Receptor modulators: e.g., propranolol (β-adrenergic antagonist), tamoxifen (estrogen receptor modulator).
• Ion channel modulators: e.g., amiodarone (K⁺ channel blocker).
• Signal pathway regulators: e.g., rapamycin (mTOR inhibitor).

Each compound is traceable to its regulatory approval status (FDA, EMA, HMA, CFDA, PMDA) or pharmacopeia listing. The library supports high-throughput screening (HTS) and high-content screening (HCS) for both phenotypic and target-based assays. Pre-dissolved 10 mM solutions in DMSO ensure uniform compound delivery and reproducibility. Solutions are formatted in 96-well microplates, deep-well blocks, or 2D barcoded tubes.

Evidence & Benchmarks

• Screening of 3,287 small molecules (including FDA-approved libraries) identified 5-aminosalicylic acid as a novel OSCAR-PPARγ axis inhibitor in murine osteoarthritis models (Kim et al., 2024).
• 5-ASA (10 mg/kg, intra-articular injection) improved cartilage thickness and decreased OA progression in DMM mouse models at both early and late intervention time points (DOI).
• Compounds stored at -20°C in DMSO remained stable for at least 12 months, with up to 24 months at -80°C, supporting repeated HTS cycles (APExBIO).
• High-throughput screening with the DiscoveryProbe™ library has enabled target identification and repositioning in cancer, neurodegenerative, and metabolic disease models (HDAC1.com).
• Mechanism-based screens using the library have revealed both pathway inhibitors and unanticipated agonists for established targets (MolecularBeacon.net).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is optimized for:

• High-throughput screening (HTS) for target identification and validation.
• Drug repositioning screens for novel indications.
• Mechanistic studies of signaling pathways (e.g., OSCAR-PPARγ axis in OA).
• Phenotypic screens in cancer, metabolic, and neurodegenerative disease models.

However, users must consider the following boundaries.

Common Pitfalls or Misconceptions

• Not all compounds are suitable for cell-based assays; some require in vivo or enzymatic context for activity.
• DMSO concentrations above 0.5% can affect cell viability and assay readouts—always verify final concentration.
• FDA-approved status does not guarantee efficacy in new indications; repositioning hits require full validation.
• Compound solubility and stability must be confirmed after thawing, especially for prolonged storage (>12 months at -20°C).
• Some drugs may have off-target effects at screening concentrations, leading to false positives or ambiguous results.

Workflow Integration & Parameters

The library is shipped on blue ice for evaluation samples, with room temperature or blue ice options for bulk orders. Upon arrival, compounds should be stored at -20°C (12 months stability) or -80°C (24 months stability). Each well contains a 10 mM DMSO solution, compatible with liquid handling robots and manual pipetting. The 96-well and deep-well formats enable scalable screening from hundreds to thousands of compounds per run. Barcode tracking supports sample traceability. Researchers should design primary screens at concentrations between 1–10 µM, followed by secondary validation at lower doses to confirm specificity (DiscoveryProbe™ FDA-approved Drug Library).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (APExBIO) is a validated, mechanism-diverse compound collection supporting drug repositioning and target identification via HTS and HCS. Its stability, clinical annotation, and flexible formats enable reproducible, scalable research. Recent studies, such as the identification of 5-ASA as an OSCAR-PPARγ axis modulator in OA, demonstrate the library's translational impact (Kim et al., 2024). As new disease models and screening technologies emerge, curated FDA-approved libraries like DiscoveryProbe™ will remain central to efficient, clinically relevant drug discovery workflows.